As the heterozygous 304Q model is characterized by an increase in plasma NfL at 6 months prior to ataxia symptom onset (Wilke et al., 2020b), a deeper understanding of pre-symptomatic NfL increases in the YACQ84 SCA3 mouse model would establish opportunity for preclinical studies to use NfL as a pre-symptomatic biomarker. Here, NEFL is linked to Ataxia.